APO Research
Talk to an analyst

APO RESEARCH · REPORT

PD-1/PD-L1 Checkpoint Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global PD-1/PD-L1 Checkpoint Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025181 pages

Choose your research edition.

Industry ResearchPD-1/PD-L1 Checkpoint Inhibitors Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal PD-1/PD-L1 Checkpoint Inhibitors Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal PD-1/PD-L1 Checkpoint Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PD-1/PD-L1 Checkpoint Inhibitors Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal PD-1/PD-L1 Checkpoint Inhibitors Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global PD-1/PD-L1 Checkpoint Inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for PD-1/PD-L1 Checkpoint Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for PD-1/PD-L1 Checkpoint Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for PD-1/PD-L1 Checkpoint Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for PD-1/PD-L1 Checkpoint Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of PD-1/PD-L1 Checkpoint Inhibitors include Merck, Junshi Biosciences, Pfizer, Hengrui Pharmaceuticals, Roche, Regeneron Pharmaceuticals, Bristol Myers Squibb and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global PD-1/PD-L1 Checkpoint Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of PD-1/PD-L1 Checkpoint Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents PD-1/PD-L1 Checkpoint Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the PD-1/PD-L1 Checkpoint Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

PD-1/PD-L1 Checkpoint Inhibitors Segment by Company

Merck

Junshi Biosciences

Pfizer

Hengrui Pharmaceuticals

Roche

Regeneron Pharmaceuticals

Bristol Myers Squibb

AstraZeneca

PD-1/PD-L1 Checkpoint Inhibitors Segment by Type

PD-1 Inhibitors

PD-L1 Inhibitors

PD-1/PD-L1 Checkpoint Inhibitors Segment by Application

Gastric Cancer

Squamous Cell Skin Cancer

Melanoma

Non-small Cell Lung Cancer

Other

PD-1/PD-L1 Checkpoint Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-1/PD-L1 Checkpoint Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PD-1/PD-L1 Checkpoint Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-1/PD-L1 Checkpoint Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the PD-1/PD-L1 Checkpoint Inhibitors market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of PD-1/PD-L1 Checkpoint Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of PD-1/PD-L1 Checkpoint Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of PD-1/PD-L1 Checkpoint Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. PD-1/PD-L1 Checkpoint Inhibitors Industry Trends Table 2. PD-1/PD-L1 Checkpoint Inhibitors Industry Drivers Table 3. PD-1/PD-L1 Checkpoint Inhibitors Industry Opportunities and Challenges Table 4. PD-1/PD-L1 Checkpoint Inhibitors Industry Restraints Table 5. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 7. Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Manufacturers Table 9. Global PD-1/PD-L1 Checkpoint Inhibitors Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global PD-1/PD-L1 Checkpoint Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global PD-1/PD-L1 Checkpoint Inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global PD-1/PD-L1 Checkpoint Inhibitors Manufacturers, Product Type & Application Table 13. Global PD-1/PD-L1 Checkpoint Inhibitors Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global PD-1/PD-L1 Checkpoint Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of PD-1 Inhibitors Table 17. Major Manufacturers of PD-L1 Inhibitors Table 18. Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Type (2021-2026) & (K Units) Table 20. Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Type (2027-2032) & (K Units) Table 21. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Type (2021-2026) Table 22. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Type (2027-2032) Table 23. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Type (2021-2026) & (K Units) Table 25. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Type (2027-2032) & (K Units) Table 26. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Type (2021-2026) Table 27. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Gastric Cancer Table 29. Major Manufacturers of Squamous Cell Skin Cancer Table 30. Major Manufacturers of Melanoma Table 31. Major Manufacturers of Non-small Cell Lung Cancer Table 32. Major Manufacturers of Other Table 33. Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Application (2021-2026) & (K Units) Table 35. Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Application (2027-2032) & (K Units) Table 36. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Application (2021-2026) Table 37. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Application (2027-2032) Table 38. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Application (2021-2026) & (K Units) Table 40. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Application (2027-2032) & (K Units) Table 41. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Application (2021-2026) Table 42. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Application (2027-2032) Table 43. Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Region (2021-2026) & (K Units) Table 45. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Region (2021-2026) Table 46. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Forecasted Market Share by Region (2027-2032) Table 48. North America PD-1/PD-L1 Checkpoint Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2021-2026) & (K Units) Table 50. North America PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2027-2032) & (K Units) Table 51. Europe PD-1/PD-L1 Checkpoint Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2021-2026) & (K Units) Table 53. Europe PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2027-2032) & (K Units) Table 60. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 62. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 63. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Region (2021-2026) Table 64. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Region (2027-2032) Table 65. Merck Company Information Table 66. Merck Business Overview Table 67. Merck PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Merck PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio Table 69. Merck Recent Development Table 70. Junshi Biosciences Company Information Table 71. Junshi Biosciences Business Overview Table 72. Junshi Biosciences PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Junshi Biosciences PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio Table 74. Junshi Biosciences Recent Development Table 75. Pfizer Company Information Table 76. Pfizer Business Overview Table 77. Pfizer PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Pfizer PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio Table 79. Pfizer Recent Development Table 80. Hengrui Pharmaceuticals Company Information Table 81. Hengrui Pharmaceuticals Business Overview Table 82. Hengrui Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Hengrui Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio Table 84. Hengrui Pharmaceuticals Recent Development Table 85. Roche Company Information Table 86. Roche Business Overview Table 87. Roche PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Roche PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio Table 89. Roche Recent Development Table 90. Regeneron Pharmaceuticals Company Information Table 91. Regeneron Pharmaceuticals Business Overview Table 92. Regeneron Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Regeneron Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio Table 94. Regeneron Pharmaceuticals Recent Development Table 95. Bristol Myers Squibb Company Information Table 96. Bristol Myers Squibb Business Overview Table 97. Bristol Myers Squibb PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Bristol Myers Squibb PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio Table 99. Bristol Myers Squibb Recent Development Table 100. AstraZeneca Company Information Table 101. AstraZeneca Business Overview Table 102. AstraZeneca PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. AstraZeneca PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio Table 104. AstraZeneca Recent Development Table 105. Key Raw Materials Table 106. Raw Materials Key Suppliers Table 107. PD-1/PD-L1 Checkpoint Inhibitors Distributors List Table 108. PD-1/PD-L1 Checkpoint Inhibitors Customers List Table 109. Research Programs/Design for This Report Table 110. Authors List of This Report Table 111. Secondary Sources Table 112. Primary Sources List of Figures Figure 1. PD-1/PD-L1 Checkpoint Inhibitors Product Image Figure 2. Global PD-1/PD-L1 Checkpoint Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PD-1/PD-L1 Checkpoint Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global PD-1/PD-L1 Checkpoint Inhibitors Sales (2021-2032) & (K Units) Figure 5. Global PD-1/PD-L1 Checkpoint Inhibitors Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 PD-1/PD-L1 Checkpoint Inhibitors Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. PD-1 Inhibitors Image Figure 9. PD-L1 Inhibitors Image Figure 10. Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Type (2021-2032) Figure 13. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Type (2021-2032) Figure 16. Gastric Cancer Image Figure 17. Squamous Cell Skin Cancer Image Figure 18. Melanoma Image Figure 19. Non-small Cell Lung Cancer Image Figure 20. Other Image Figure 21. Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Application (2021-2032) Figure 24. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Application (2021-2032) Figure 27. North America PD-1/PD-L1 Checkpoint Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Country (2021-2032) Figure 29. U.S. PD-1/PD-L1 Checkpoint Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada PD-1/PD-L1 Checkpoint Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico PD-1/PD-L1 Checkpoint Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe PD-1/PD-L1 Checkpoint Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Country (2021-2032) Figure 34. Germany PD-1/PD-L1 Checkpoint Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France PD-1/PD-L1 Checkpoint Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. PD-1/PD-L1 Checkpoint Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy PD-1/PD-L1 Checkpoint Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands PD-1/PD-L1 Checkpoint Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Country (2021-2032) Figure 41. China PD-1/PD-L1 Checkpoint Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan PD-1/PD-L1 Checkpoint Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea PD-1/PD-L1 Checkpoint Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia PD-1/PD-L1 Checkpoint Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India PD-1/PD-L1 Checkpoint Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia PD-1/PD-L1 Checkpoint Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Country (2021-2032) Figure 49. Brazil PD-1/PD-L1 Checkpoint Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa PD-1/PD-L1 Checkpoint Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia PD-1/PD-L1 Checkpoint Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey PD-1/PD-L1 Checkpoint Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina PD-1/PD-L1 Checkpoint Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE PD-1/PD-L1 Checkpoint Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt PD-1/PD-L1 Checkpoint Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile PD-1/PD-L1 Checkpoint Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America PD-1/PD-L1 Checkpoint Inhibitors Revenue (2021-2032) & (US$ Million) Figure 60. North America PD-1/PD-L1 Checkpoint Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe PD-1/PD-L1 Checkpoint Inhibitors Revenue (2021-2032) & (US$ Million) Figure 62. Europe PD-1/PD-L1 Checkpoint Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. PD-1/PD-L1 Checkpoint Inhibitors Value Chain Figure 68. Manufacturing Cost Structure Figure 69. PD-1/PD-L1 Checkpoint Inhibitors Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • PD-1 Inhibitors
  • PD-L1 Inhibitors
Applications
  • Gastric Cancer
  • Squamous Cell Skin Cancer
  • Melanoma
  • Non-small Cell Lung Cancer
  • Other
Companies covered
  • Merck
  • Junshi Biosciences
  • Pfizer
  • Hengrui Pharmaceuticals
  • Roche
  • Regeneron Pharmaceuticals
  • Bristol Myers Squibb
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global PD-1/PD-L1 Checkpoint Inhibitors Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global PD-1/PD-L1 Checkpoint Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global PD-1/PD-L1 Checkpoint Inhibitors Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global PD-1/PD-L1 Checkpoint Inhibitors Market Dynamics
  1. 2.1 PD-1/PD-L1 Checkpoint Inhibitors Industry Trends
  2. 2.2 PD-1/PD-L1 Checkpoint Inhibitors Industry Drivers
  3. 2.3 PD-1/PD-L1 Checkpoint Inhibitors Industry Opportunities and Challenges
  4. 2.4 PD-1/PD-L1 Checkpoint Inhibitors Industry Restraints
3 PD-1/PD-L1 Checkpoint Inhibitors Market by Manufacturers
  1. 3.1 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Manufacturers (2021-2026)
  2. 3.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Manufacturers (2021-2026)
  3. 3.3 Global PD-1/PD-L1 Checkpoint Inhibitors Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global PD-1/PD-L1 Checkpoint Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global PD-1/PD-L1 Checkpoint Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global PD-1/PD-L1 Checkpoint Inhibitors Manufacturers, Product Type & Application
  7. 3.7 Global PD-1/PD-L1 Checkpoint Inhibitors Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global PD-1/PD-L1 Checkpoint Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 PD-1/PD-L1 Checkpoint Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 PD-1/PD-L1 Checkpoint Inhibitors Tier 1, Tier 2, and Tier 3
4 PD-1/PD-L1 Checkpoint Inhibitors Market by Type
  1. 4.1 PD-1/PD-L1 Checkpoint Inhibitors Type Introduction
  2. 4.1.1 PD-1 Inhibitors
  3. 4.1.2 PD-L1 Inhibitors
  4. 4.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Type
  5. 4.2.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Type (2021-2032)
  7. 4.2.3 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Type (2021-2032)
  8. 4.3 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Type
  9. 4.3.1 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Type (2021-2032)
  11. 4.3.3 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Type (2021-2032)
5 PD-1/PD-L1 Checkpoint Inhibitors Market by Application
  1. 5.1 PD-1/PD-L1 Checkpoint Inhibitors Application Introduction
  2. 5.1.1 Gastric Cancer
  3. 5.1.2 Squamous Cell Skin Cancer
  4. 5.1.3 Melanoma
  5. 5.1.4 Non-small Cell Lung Cancer
  6. 5.1.5 Other
  7. 5.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Application
  8. 5.2.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Application (2021-2032)
  10. 5.2.3 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Application (2021-2032)
  11. 5.3 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Application
  12. 5.3.1 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Application (2021-2032)
  14. 5.3.3 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Application (2021-2032)
6 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Region
  1. 6.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Region (2021-2026)
  4. 6.2.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America PD-1/PD-L1 Checkpoint Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe PD-1/PD-L1 Checkpoint Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Region
  1. 7.1 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Region
  2. 7.1.1 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Region (2021-2026)
  4. 7.1.3 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Region (2027-2032)
  5. 7.1.4 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America PD-1/PD-L1 Checkpoint Inhibitors Revenue (2021-2032)
  8. 7.2.2 North America PD-1/PD-L1 Checkpoint Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe PD-1/PD-L1 Checkpoint Inhibitors Revenue (2021-2032)
  11. 7.3.2 Europe PD-1/PD-L1 Checkpoint Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck PD-1/PD-L1 Checkpoint Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 Junshi Biosciences
  8. 8.2.1 Junshi Biosciences Company Information
  9. 8.2.2 Junshi Biosciences Business Overview
  10. 8.2.3 Junshi Biosciences PD-1/PD-L1 Checkpoint Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Junshi Biosciences PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio
  12. 8.2.5 Junshi Biosciences Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer PD-1/PD-L1 Checkpoint Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 Hengrui Pharmaceuticals
  20. 8.4.1 Hengrui Pharmaceuticals Company Information
  21. 8.4.2 Hengrui Pharmaceuticals Business Overview
  22. 8.4.3 Hengrui Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Hengrui Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio
  24. 8.4.5 Hengrui Pharmaceuticals Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche PD-1/PD-L1 Checkpoint Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Roche PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 Regeneron Pharmaceuticals
  32. 8.6.1 Regeneron Pharmaceuticals Company Information
  33. 8.6.2 Regeneron Pharmaceuticals Business Overview
  34. 8.6.3 Regeneron Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Regeneron Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio
  36. 8.6.5 Regeneron Pharmaceuticals Recent Developments
  37. 8.7 Bristol Myers Squibb
  38. 8.7.1 Bristol Myers Squibb Company Information
  39. 8.7.2 Bristol Myers Squibb Business Overview
  40. 8.7.3 Bristol Myers Squibb PD-1/PD-L1 Checkpoint Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Bristol Myers Squibb PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio
  42. 8.7.5 Bristol Myers Squibb Recent Developments
  43. 8.8 AstraZeneca
  44. 8.8.1 AstraZeneca Company Information
  45. 8.8.2 AstraZeneca Business Overview
  46. 8.8.3 AstraZeneca PD-1/PD-L1 Checkpoint Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 AstraZeneca PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio
  48. 8.8.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 PD-1/PD-L1 Checkpoint Inhibitors Value Chain Analysis
  2. 9.1.1 PD-1/PD-L1 Checkpoint Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 PD-1/PD-L1 Checkpoint Inhibitors Production Mode & Process
  6. 9.2 PD-1/PD-L1 Checkpoint Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 PD-1/PD-L1 Checkpoint Inhibitors Distributors
  9. 9.2.3 PD-1/PD-L1 Checkpoint Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst